Highlights of This Issue 3097

SPECIAL FEATURES

CCR 20th Anniversary Commentary

3099 CCR 20th Anniversary Commentary: Chimeric Antigen Receptors—From Model T to the Tesla
Patrick Hwu

CCR Translations

3102 Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, and Jennifer A. Wargo
See related article, p. 3140

3105 Growth Factor Receptor Fusions Predict Therapeutic Sensitivity
Manmeet S. Ahluwalia and Jeremy N. Rich
See related article p. 3307

Molecular Pathways

3108 Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Diletta Di Mitri, Alberto Toso, and Andrea Alimonti

Reviews

3113 Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa, Suparna Dutt, Cariad Chester, Jeewon Kim, and Holbrook E. Kohrt

3121 Nanotechnology: Future of Oncotherapy
Kshipra M. Gharpure, Sherry Y. Wu, Chun Li, Gabriel Lopez-Berestein, and Anil K. Sood

CANCER THERAPY: CLINICAL

3131 Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning
Muriel Hannon, Yves Beguin, Grégoire Ehr, Sophie Servais, Laurence Seidel, Carlos Gaux, Johan Maertens, Tessa Kerre, Coline Daule, Muriel de Bock, Marianne Fillet, Aurélie Ory, Evelyne Willems, André Godot, Stéphanie Humbert-Baron, and Frédéric Baron

3140 PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
See related commentary, p. 3162

3149 Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA* Liver Metastases

3159 Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, and Earle O. Assanali

3170 Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, and Partha Nandy

3178 Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allsop, Catia Fonseca, Yukoh Nakazaki, David Nemere, Chandrajit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritzi, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, and Glenn Dungan

PERSONALIZED MEDICINE AND IMAGING

3187 Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
3196 Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Vioire Sivagnong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Melilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Mei, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, and Lin Wu

CANCER THERAPY: PRECLINICAL

3204 Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas Misu Lee, Tobias Wiedemann, Claudia Gross, Ines Leinhäuser, Federico Roncaroli, Rickmer Braren, and Natalia S. Pellegrata


3230 HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIP, Robbie Carson, Basak Celikci, Cathy Fenning, Arman Javadi, Nyree Crawford, Lucia Perez-Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, and Sandra Van Schaeybroeck


3252 An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Jyoti Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sachanaka, Josh Tanguay, Susan Spencer, Sreedevi Chalasani, Elizabeth Luis, Karen Gascoigne, Rupal Desai, Rajiv Raja, Brad A. Friedman, Peter M. Haventy, Paul Polakis, and Ron Firestein

3263 Targeting Glutamine Metabolism in Breast Cancer with Aminoxyacetate Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mor, Charlotte M. Huijts, Horne Wildef, Santosh Bharti, Zhe Zhang, Cesar A. Santa-Maria, Hualing Tsai, Chi V. Dang, Vered Stearns, Zaver M. Bhujwalla, and Saraswati Sukumar


3286 XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A Takahito Miyake, Sunila Pradeep, Sherry Y. Wu, Rajesha Rupainmoole, Belrouz Zand, Yunfei Wen, Kishpra M. Gharpure, Archanas S. Nagaraja, Wei Hu, Min Soon Cho, Heather J. Dalton, Rebecca A. Previs, Morgan L. Taylor, Takeshi Hisamatsu, Yu Kang, Tao Liu, Sharon Shacham, Dilara McCauley, David H. Hawke, John E. Wiktowicz, Robert L. Coleman, and Anil K. Sood

3298 A Novel Anti-CD22 Anthraeycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Shang-Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan Spencer, Helga Raab, Robert Sotiano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John Flygare, and Andrew G. Polson


3318 Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting Hongda Chen, Manuela Zucknick, Simone Werner, Phillip Knebel, and Hermann Brenner
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment


Genetic Modulation of Neurocognitive Function in Glioma Patients

Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Wefel

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer


Correction: Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire

The heatmap shows expression of immune-related genes in endometrial cancers from the TCGA series. POLE proofreading-mutant tumors display evidence of a robust cytotoxic T-cell response. For details, see the article by van Gool and colleagues on page 3347 of this issue.